FDA approvals in 2025 included Anktiva, mitomycin, and gemcitabine intravesical systems for BCG-unresponsive and low-grade intermediate-risk NMIBC. Real-world data supported the efficacy and safety of ...

RCT compares platinum/5-FU, platinum/paclitaxel in high-risk penile cancer ...

Martin B. Richman, MD, MBA, FACS, outlines recent advancements in BPH, with an emphasis on the importance of a patient-focused approach to care.

"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and ...

Cycling has multiple benefits, and steps can be taken to prevent genitourinary injury. Bicycling across the globe is increasing as a means of exercise and transportation. Clinicians need to be ...

Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term ...

A new analysis supports return to widespread screening. A reevaluation of the tradeoffs of prostate cancer screening using the most recent data should rewrite the negative narrative associated with ...

In this interview, Seth P. Lerner, MD, discusses current recommendations for managing patients during the BCG shortage, what the FDA is doing to resolve the problem, and a SWOG trial testing a new ...

Researchers at the Mayo Clinic report that they have developed a legitimate penile traction therapy device for men with Peyronie’s disease that may work when used for just 30 to 90 minutes daily.

Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important ...

"An alternative off-label option for patients with BCG-unresponsive NMIBC is sequential intravesical gemcitabine and docetaxel (Gem/Doce)," write Rachel Passarelli, MD, and Vignesh T. Packiam, MD.

"We knew that the MS or momentary squeeze pump, originally designed at AMS was a fine device, but it did have some issues. We thought we could make it even better," says Ronald A. Morton, MD. The ...